Scholarlink

Background <p>Accurate estimation of lesion-specific effective half-life (T<sub>eff</sub>) is essential for patient-specific dosimetry in radioiodine (I-131) therapy for differentiated thyroid cancer (DTC). Although conventional multi-timepoint imaging provides detailed kinetic information, it is often impractical for routine clinical implementation. This study prospectively evaluated a simplified dual-timepoint planar imaging protocol aimed at balancing quantitative reliability with clinical feasibility.</p> Methods <p>Fifty patients with DTC undergoing I-131 therapy were prospectively analyzed. Whole-body planar images were acquired twice after administration: an early scan at 1.98–3.25 days (mean, 2.71 days) and a delayed scan at 8.97–17.16 days (interval between the two scans ranged from 6.18 to 14.28 days [mean, 12.35 days]). Lesion-specific T<sub>eff</sub> values were calculated assuming mono-exponential clearance between the two scans using a log-linear approximation of measured activity counts. Quantitative reproducibility was assessed by comparing activity–count calibration slopes derived from an internal reference I-131 capsule between independent imaging sessions.</p> Results <p>The mean T<sub>eff</sub> was 2.16 ± 0.56 days and 3.11 ± 0.74 days for thyroid bed (<i>n</i> = 35) and metastatic (<i>n</i> = 19; <i>p</i> &lt; 0.001) lesions, respectively. Among metastatic sites, bone and lung metastases showed numerically similar T<sub>eff</sub> values (3.22 ± 0.76 and 3.36 ± 0.80 days, respectively); however, this subgroup comparison was limited by the small sample size. Calibration slopes derived from the internal reference capsule demonstrated only 5.0% inter-session variability, indicating high quantitative reproducibility.</p> Conclusions <p>Dual-timepoint planar imaging incorporating internal capsule calibration enables reproducible estimation of lesion-specific T<sub>eff</sub> in patients undergoing I-131 therapy for DTC. This approach achieves a practical balance between quantitative accuracy and clinical feasibility, enabling reliable characterization of iodine kinetics with minimal imaging burden and supporting individualized dosimetry in routine clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Estimation of effective half-life and lesion-specific kinetics in I-131 therapy for differentiated thyroid cancer using dual-timepoint imaging

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Yusuke Iizuka,
  • Ryota Nakashima,
  • Rihito Aizawa,
  • Masaaki Kajisako,
  • Maki Shioji,
  • Katsuhiko Mitsumoto,
  • Koji Itagaki,
  • Shigeto Kawase,
  • Takashi Mizowaki

摘要

Background

Accurate estimation of lesion-specific effective half-life (Teff) is essential for patient-specific dosimetry in radioiodine (I-131) therapy for differentiated thyroid cancer (DTC). Although conventional multi-timepoint imaging provides detailed kinetic information, it is often impractical for routine clinical implementation. This study prospectively evaluated a simplified dual-timepoint planar imaging protocol aimed at balancing quantitative reliability with clinical feasibility.

Methods

Fifty patients with DTC undergoing I-131 therapy were prospectively analyzed. Whole-body planar images were acquired twice after administration: an early scan at 1.98–3.25 days (mean, 2.71 days) and a delayed scan at 8.97–17.16 days (interval between the two scans ranged from 6.18 to 14.28 days [mean, 12.35 days]). Lesion-specific Teff values were calculated assuming mono-exponential clearance between the two scans using a log-linear approximation of measured activity counts. Quantitative reproducibility was assessed by comparing activity–count calibration slopes derived from an internal reference I-131 capsule between independent imaging sessions.

Results

The mean Teff was 2.16 ± 0.56 days and 3.11 ± 0.74 days for thyroid bed (n = 35) and metastatic (n = 19; p < 0.001) lesions, respectively. Among metastatic sites, bone and lung metastases showed numerically similar Teff values (3.22 ± 0.76 and 3.36 ± 0.80 days, respectively); however, this subgroup comparison was limited by the small sample size. Calibration slopes derived from the internal reference capsule demonstrated only 5.0% inter-session variability, indicating high quantitative reproducibility.

Conclusions

Dual-timepoint planar imaging incorporating internal capsule calibration enables reproducible estimation of lesion-specific Teff in patients undergoing I-131 therapy for DTC. This approach achieves a practical balance between quantitative accuracy and clinical feasibility, enabling reliable characterization of iodine kinetics with minimal imaging burden and supporting individualized dosimetry in routine clinical practice.